Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael E. Rytting, MD
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University Medical Center
Stanford, California, United States
- Children'S Memorial Hospital
Chicago, Illinois, United States
- Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
- Children'S Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
- St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
- University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2009
- Primary completion
- 30 Apr 2015
- Completion
- 30 Apr 2015
- Last update posted
- 26 Aug 2020
- Registered enrollment
- 24
- Registry id
- NCT00883688
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.